AUSTIN, Texas, Sept. 11, 2018 /PRNewswire/
-- Luminex Corporation (Nasdaq:LMNX) (the "Company"),
today announced that its board of directors declared a cash
dividend for the third quarter of 2018 of $0.06 per share of common stock payable on
October 12, 2018 to stockholders
of record as of the close of business September 21, 2018.
About Luminex Corporation
At Luminex, our mission is
to empower labs to obtain reliable, timely, and actionable answers,
ultimately advancing health. We offer a wide range of
solutions applicable in diverse markets including clinical
diagnostics, pharmaceutical drug discovery, biomedical research,
genomic and proteomic research, biodefense research, and food
safety. We accelerate reliable answers while simplifying complexity
and deliver certainty with a seamless experience. To learn more
about Luminex, please visit us at www.luminexcorp.com.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward-looking statements in this release include statements
regarding expected revenue and cost savings and projected 2018
performance, including revenue guidance. The words "believe,"
"expect," "intend," "estimate," "anticipate," "will," "could,"
"should" and similar expressions are intended to further identify
such forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. It is important to
note that the Company's actual results or performance could differ
materially from those anticipated or projected in such
forward-looking statements. Factors that could cause
Luminex's actual results or performance to differ materially
include risks and uncertainties relating to, among others,
concentration of Luminex's revenue in a limited number of direct
customers and strategic partners, some of which may be experiencing
decreased demand for their products utilizing or incorporating
Luminex's technology, budget or finance constraints in the current
economic environment, or periodic variability in their purchasing
patterns or practices as a result of internal resource
planning challenges; market demand and acceptance of Luminex's
products and technology, including ARIES®,
MultiCode®, xMAP®,
VERIGENE® and NxTAG® products;
Luminex's ability to scale manufacturing operations and manage
operating expenses, gross margins and inventory levels; Luminex's
ability to obtain and enforce intellectual property protections on
Luminex's products and technologies; the impact on Luminex's growth
and future results of operations with respect to the loss of the
LabCorp women's health business anticipated in June 2018; Luminex's ability to successfully
launch new products in a timely manner; dependence on strategic
partners for development, commercialization and distribution of
products; risks and uncertainties associated with implementing
Luminex's acquisition strategy, Luminex's challenge to identify
acquisition targets, including Luminex's ability to obtain
financing on acceptable terms; Luminex's ability to integrate
acquired companies or selected assets into Luminex's consolidated
business operations, and the ability to fully realize the benefits
of Luminex's acquisitions; the timing of and process for regulatory
approvals; competition and competitive technologies utilized by
Luminex's competitors; fluctuations in quarterly results due to a
lengthy and unpredictable sales cycle; fluctuations in bulk
purchases of consumables; fluctuations in product mix, and the
seasonal nature of some of Luminex's assay products; Luminex's
ability to comply with applicable laws, regulations, policies and
procedures; the impact of the ongoing uncertainty in global finance
markets and changes in governmental and governmental agency
funding, including effects on the capital spending policies of
Luminex's partners and end users and their ability to finance
purchases of Luminex's products; changes in interpretation,
assumptions and expectations regarding the Tax Cuts and Jobs Act,
including additional guidance that may be issued by federal and
state taxing authorities; changes in principal members of Luminex's
management staff; potential shortages, or increases in costs, of
components or other disruptions to Luminex's manufacturing
operations; Luminex's increasing dependency on information
technology to improve the effectiveness of Luminex's operations and
to monitor financial accuracy and efficiency; the implementation,
including any modification, of Luminex's strategic operating plans;
the uncertainty regarding the outcome or expense of any
litigation brought against or initiated by Luminex; risks relating
to Luminex's foreign operations, including fluctuations in exchange
rates, tariffs, customs and other barriers to importing/exporting
materials and products in a cost effective and timely manner;
difficulties in accounts receivable collections; Luminex's ability
to monitor and comply with foreign and international laws and
treaties; and Luminex's ability to comply with changes in
international taxation policies; budget or finance constraints in
the current economic environment, or periodic variability in their
purchasing patterns or practices as a result of material resource
planning challenges; reliance on third party distributors for
distribution of specific Luminex-developed and manufactured assay
products, as well as the risks discussed under the heading "Risk
Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with
the Securities and Exchange Commission. The forward-looking
statements, including the financial guidance and 2018 outlook,
contained herein represent the judgment of Luminex as of the date
of this press release, and Luminex expressly disclaims any intent,
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in Luminex's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Contact:
Harriss Currie
Senior Vice President and Chief Financial Officer
512-219-8020
hcurrie@luminexcorp.com
David Carey
Investor Relations
Lazar Partners
212-867-1768
dcarey@lazarpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/luminex-corporation-declares-third-quarter-cash-dividend-300710567.html
SOURCE Luminex Corporation